ClinicalTrials.gg
Status unknownNCT03313596Updated Feb 4, 2019

Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC

A Phase 3 interventional study of ADV-Tk and LT in Hepatocellular Carcinoma, sponsored by Huazhong University of Science and Technology. Status unknown at 11 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-02-04.

Sponsored by Huazhong University of Science and Technology · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Carcinoma, Hepatocellular by Huazhong University of Science and Technology — none open to participants now, none under way, none of them phase 3. Carcinoma, Hepatocellular · Huazhong University of Science and Technology.

Started
2013
the only one that year
Phase 3
Only one
of the 10
Registered
5th of 10
by date

Among the 10 studies in Carcinoma, Hepatocellular by Huazhong University of Science and Technology, this one is the only one that started in 2013, is the only one in phase 3, and was the 5th registered.

Carcinoma, Hepatocellular

3,652 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

None of the 10 studies in Carcinoma, Hepatocellular by Huazhong University of Science and Technology is open now. The open studies under Carcinoma, Hepatocellular, anywhere →

Where they have run

Who these studies take

Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Carcinoma, Hepatocellular by Huazhong University of Science and Technology as a file.
02

Study summary

Compare the effect of liver transplantation (LT) plus ADV-TK gene therapy versus LT only in advanced primary hepatocellular carcinoma.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 - 65 years of age (Male and Female).
  • Clinical diagnosis of advanced primary hepatocellular carcinoma who could accept liver transplantation.
  • Patients who had unresectable HCC with single tumor diameter > 5 cm and ≤ 10cm; or numbers of multiple tumors >3 and ≤ 5, and the total length of foci diameter ≤ 15 cm.
  • Serum AFP ≤ 10000 ng/ml before liver transplantation.
  • A-B.
  • No in extrahepatic main vescular and extrahepatic lymph node detected during the operation and no metastasis of other organs.
  • Provide written before screening.

Exclusion criteria

Exclusion Criteria:

  • in extrahepatic organs.
  • HCC with Invasion in extrahepatic main vescular and extrahepatic organs.
  • of operation of other organ system.
  • to adenovirus, GCV or similar drugs.
  • Serious obstacle of the mechanism of coagulation, hemorrhagic tendency, and abnormal coagulation (≥50%).
  • Plan to accept clinical trials of other antitumor drugs.
  • Immunological deficit.
  • (+) and HBcAb(+) donor.
  • Unsuitable participate assessed by investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    LT-only

    patients received orthotopic LT and subsequent immunosuppression therapy

    Procedure: LT

  • Experimental
    LT+ADV-TK

    ADV-TK therapy was administered in addition to orthotopic LT and subsequent immunosuppression therapy

    Drug: ADV-Tk · Procedure: LT

Interventions

  • DrugADV-Tk

    The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver. The second and third ADV-TK dose was administered 60 days and 90 days after LT; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into the celiac artery (60 mL) and the superior mesenteric artery (40 mL) via femoral-artery puncture.

  • ProcedureLT

    Orthotopic LT and subsequent immunosuppression therapy

06

What researchers measure

Primary outcomes

  1. Progression-free survival, PFS

    PFS was measured from the day of liver transplantation to objective recurrence (MRI or CT) or HCC-related death, whichever occurred first.

    Time frame: 2-year

Secondary outcomes

  1. Overall survival, OS

    OS was measured from the day of liver transplantation to death.

    Time frame: 1-year

  2. Overall survival, OS

    OS was measured from the day of liver transplantation to death.

    Time frame: 2-year

  3. Time of the tumor progression,TTP

    TTP was the median period from the day of liver transplantation to objective recurrence (MRI or CT).

    Time frame: 2-year

  4. Median overall survival time

    Time frame: 2-year

07

Study locations

11 of 11 sites recruiting
  • Beijing Youan Hospital
    Beijing, Beijing 10001, China
    Recruiting
    • Ning Li, Dr · Contact
  • 301 Military Hospital
    Beijing, China
    Recruiting
    • Jiahong Dong · Contact
  • General Hospital of Chinese People's Armed Police
    Beijing, China
    Recruiting
    • Yunjin Zang · Contact
  • The Third XiangYa Hospital of Central South University
    Changsha, China
    Recruiting
    • Qifa Ye · Contact
  • West China Hospital of Sichuan University
    Chengdu, China
    Recruiting
    • Lvnan Yan · Contact
  • The Third Affiliated Hospital,Sun Yat-sen University
    Guangzhou, China
    Recruiting
    • Guihua Chen · Contact
  • The First Affiliated Hospital, Zhejiang University
    Hangzhou, China
    Recruiting
    • Shusen Zheng · Contact
  • Zhongshan Hospital of Fudan University
    Shanghai, China
    Recruiting
    • Jia Fan · Contact
  • The First Affiliated Hospital of China Medical University
    Shenyang, China
    Recruiting
    • Yongfeng Liu · Contact
  • The First Center Hospital of Tianjin
    Tianjin, China
    Recruiting
    • Zhongyang Shen · Contact
  • The First Hospital of Xinjiang Medical University
    Urumqi, China
    Recruiting
    • Hao Wen · Contact
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Dec 2019 and a completion of Dec 2019. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2017
First posted
Oct 18, 2017
Start
Mar 2013
Primary completionEst.
Dec 2019
CompletionEst.
Dec 2019
Last update
Feb 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03313596
Collaborators
Beijing YouAn Hospital
Responsible party
Ding Ma (Director, Huazhong University of Science and Technology) — Principal investigator
First posted
Oct 18, 2017
Start date
Mar 2013
Primary completion
Dec 2019 (estimated)
Completion
Dec 2019 (estimated)
Last update
Feb 4, 2019

Study contacts

Danhui Weng, Dr.
Contact
weng.dh@gmail.com
027-83663351

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aglatimagene besadenovec

Start the discussion